NCT06344572招募中不适用
A Multicenter, Randomized, Open-label, Controlled Pivotal Study to Evaluate the Efficacy and Safety of Software SAT-001 in Slowing Myopia Progression and Treatment in Pediatric Patients With Myopia
S-Alpha Therapeutics, Inc.2 个研究点 分布在 2 个国家目标入组 110 人开始时间: 2023年9月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 110
- 试验地点
- 2
- 主要终点
- Change in Axial Length
研究概览
简要总结
The objective of this clinical investigation is to evaluate the efficacy and safety of SAT-001 designed as Software as Medical Device (SaMD) for slowing myopia progression and treatment in pediatric myopia patients.
详细描述
Myopia is a common refractive error affecting approximately 30 % of the global population, with even higher prevalence in Asian countries including Korea. This study is a confirmatory clinical trial designed to evaluate the efficacy and safety of SAT-001 for slowing the progression of myopia in children, based on the results of the exploratory clinical trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 5 Years 至 8 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Children aged 5 to less than 9
- •Meet the following refractive criteria by cycloplegic refraction
- •Spherical equivalent refractive error (SER): -0.75 to less than -6.00 D in each eye
- •Astigmatism of 1.50 D or less in each eye
- •Anisometropia of 2.00 D or less
- •Best corrected visual acuity of 0.2 logMAR or better in each eye at the Screening Visit
- •Able to successfully accomplish SAT-001, the investigational device (able to follow the written and verbal instruction)
- •Subjects and their legal guardians who agree to participate in the clinical trial and are willing to provide the signed informed consent after receiving and comprehending the explanation of the description of this clinical trial (subject under 6 can make a mark for agreement after full information and understanding)
排除标准
- •History of atropine use within 3 days prior to Baseline (Visit 2) (prior treatment of myopia control with low dose atropine within 1 month prior to Baseline)
- •Current or prior use of multifocal lenses (e.g. progressive addition lenses), orthokeratology (Ortho-K, e.g. Dream lens), or Rigid gas permeable (RGP) within 1month prior to Baseline(Visit 2)
- •Ocular abnormalities in cornea, lens, central retina, iris, ciliary body, etc., or presence of malignant tumors in the orbital area
- •History of eye diseases such as manifest strabismus, intermittent strabismus, amblyopia, and nystagmus (excluding strabismus that maintains binocular vision)
- •History of ocular surgery such as eyelid surgery, strabismus surgery, intraocular surgery, or refractive correction surgery (excluding simple double eyelid surgery)
- •Down's syndrome or cerebral palsy
- •Within 6 months prior to the Screening visit (Visit 1), has experience of other clinical trial medications or investigational device
- •Clinically significant systemic diseases such as congenital heart disease, respiratory disease, endocrine disease, and neurological disease that the investigator may consider inappropriate for participation in the clinical trials
- •Systemic diseases that could impact both vision and visual field
- •History of growth hormone treatment within 1 month prior to Baseline (Visit 2)
- •Other reasons for participation in the trial at the discretion of the investigator
结局指标
主要结局
Change in Axial Length
时间窗: Baseline, 48weeks
次要结局
- Change in cycloplegic Spherical Equivalent Refractive Error relative to baseline depending on the myopia severity(mild myopia, moderate myopia)(Baseline, 24 weeks, 48 weeks)
- Change in axial length relative to baseline depending on the myopia severity(mild myopia, moderate myopia)(Baseline, 12weeks, 24weeks, 36weeks, 48weeks)
- Change in Axial Length(Baseline, 12weeks, 24weeks, 36weeks)
- Change in cycloplegic Spherical Equivalent Refractive Error(Baseline, 24weeks, 48weeks)
- Change in cycloplegic Spherical Equivalent Refractive Error relative to baseline depending on the myopia severity(mild myopia, moderate myopia)(Baseline, 24 weeks, 48 weeks)
- Change in axial length relative to baseline depending on the myopia severity(mild myopia, moderate myopia)(Baseline, 12weeks, 24weeks, 36weeks, 48weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Exploratory Study of SAT-001 in Treatment of Pediatric Patient With MyopiaChildren MyopiaNCT05917041S-Alpha Therapeutics, Inc.60
已完成
不适用
Pivotal Trial of SAT-014 for Trauma and Stressor-Related Disorder SymptomsAdjustment DisordersPost-traumatic Stress DisorderNCT06734858S-Alpha Therapeutics, Inc.110
已完成
不适用
Exploratory Trial of SAT-003 in Cancer Cachexia Patients With Discontinued ChemotherapyCancer CachexiaNCT06476197S-Alpha Therapeutics, Inc.15
终止
1 期
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETsNeuroendocrine TumorsNCT02592707Ipsen40
终止
1 期
Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or LymphomasAdvanced/Metastatic Solid Tumors or LymphomasNCT02675439Chinook Therapeutics, Inc. (formerly Aduro)47